Health care pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 health care pharmaceutical companies ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8). Figures as of 19 Nov 2026, 23:53 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 39.3
- Combined market value
- CHF 4.19T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | CHF 3.8B | CHF 34.75 | 0.48% down | 86% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | CHF 16.7B | CHF 124.77 | 1.06% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 9.8 | CHF 144.6B | CHF 32.81 | 1.42% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 9.9 | CHF 4.7B | CHF 6.92 | 3.19% down | 0% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 12.9 | CHF 100.7B | CHF 49.24 | 2.05% down | 30% up | ||
| 6 | ZoetisZTS · Health Care | 13.7 | CHF 27.7B | CHF 68.19 | 5.59% down | 26% down | ||
| 7 | GSKGSK · Health Care | 16.7 | CHF 80.9B | CHF 40.36 | 1.56% down | 5% up | ||
| 8 | Ascendis PharmaASND · Health Care | 16.8 | CHF 14.2B | CHF 216.04 | 5.32% down | 29% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 20.4 | CHF 80.6B | CHF 779.34 | 2.35% down | 28% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.1 | CHF 20.1B | CHF 471.90 | 3.16% down | 22% up | ||
| 11 | SanofiSNY · Health Care | 22.9 | CHF 93.4B | CHF 38.88 | 2.25% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 24.8 | CHF 229.6B | CHF 148.05 | 1.87% down | 1% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.2 | CHF 6.8B | CHF 104.68 | 2.47% down | 51% up | ||
| 14 | NovartisNVS · Health Care | 28.9 | CHF 241.1B | CHF 127.64 | 2.57% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 33.5 | CHF 111.4B | CHF 439.46 | 2.94% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.8 | CHF 151.8B | CHF 87.67 | 0.58% down | 16% down | ||
| 17 | PfizerPFE · Health Care | 39.3 | CHF 132.5B | CHF 23.24 | 1.85% down | 15% up | ||
| 18 | Johnson & JohnsonJNJ · Health Care | 40.5 | CHF 542.8B | CHF 225.48 | 2.04% down | 34% up | ||
| 19 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.2 | CHF 10.4B | CHF 12.52 | 1.00% down | 8% up | ||
| 20 | Eli LillyLLY · Health Care | 43.9 | CHF 1.02T | CHF 1,140.40 | 2.29% down | 33% up | ||
| 21 | GenmabGMAB · Health Care | 43.9 | CHF 26.7B | CHF 43.34 | 0.75% up | 70% up | ||
| 22 | Royalty PharmaRPRX · Health Care | 44.3 | CHF 32.9B | CHF 57.16 | 1.38% down | 79% up | ||
| 23 | AbbVieABBV · Health Care | 48.7 | CHF 423B | CHF 239.32 | 0.86% down | 25% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 48.9 | CHF 6B | CHF 54.85 | 4.15% down | 10% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.2 | CHF 38.5B | CHF 337.36 | 0.97% down | 16% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.5 | CHF 6.3B | CHF 18.05 | 2.24% down | 90% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 70.0 | CHF 12.8B | CHF 199.57 | 4.57% down | 41% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 70.9 | CHF 6.2B | CHF 78.95 | 1.59% down | 129% up | ||
| 29 | Teva Pharmaceutical IndustriesTEVA · Health Care | 89.6 | CHF 38B | CHF 32.53 | 8.74% down | 74% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | 96.8 | CHF 8.3B | CHF 54.76 | 1.88% down | 117% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 115 | CHF 4.8B | CHF 242.19 | 3.94% down | 50% up | ||
| 32 | Merck & CoMRK · Health Care | 134 | CHF 276.3B | CHF 112.10 | 3.61% down | 45% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 306 | CHF 57.7B | CHF 18.07 | 0.66% up | 51% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8440 CHF). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8) have the lowest P/E ratio of the 33 health care pharmaceutical companies ranked here as of 19 Nov 2026, 23:53 UTC.
How many health care pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 33 health care pharmaceutical companies ranked by P/E ratio have a combined market value of CHF 4.19T as of 19 Nov 2026, 23:53 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care pharmaceutical companies by P/E ratio”, data as of 19 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.